Despite QoL data being available for most cancer treatments recently approved by regulatory agencies, QoL improvement has been demonstrated in a minority of studies with positive results in the primary endpoint.
Keyphrases
- phase iii
- open label
- double blind
- clinical trial
- placebo controlled
- phase ii
- papillary thyroid
- palliative care
- randomized controlled trial
- transcription factor
- electronic health record
- study protocol
- emergency department
- squamous cell carcinoma
- drug induced
- drug administration
- deep learning
- adipose tissue
- adverse drug
- insulin resistance